PROVABGS: The Probabilistic Stellar Mass Function of the BGS One-percent Survey

We present the probabilistic stellar mass function (pSMF) of galaxies in the DESI Bright Galaxy Survey (BGS), observed during the One-percent Survey. The One-percent Survey was one of DESI’s survey validation programs conducted from 2021 April to May, before the start of the main survey. It used the same target selection and similar observing strategy as the main survey and successfully observed the spectra and redshifts of 143,017 galaxies in the r 100 × more galaxies. Moreover, we present the statistical framework for subsequent population statistics measurements using BGS, which will characterize the global galaxy population and scaling relations at low redshifts with unprecedented precision

PROVABGS: The Probabilistic Stellar Mass Function of the BGS One-Percent Survey

We present the probabilistic stellar mass function (pSMF) of galaxies in the DESI Bright Galaxy Survey (BGS), observed during the One-Percent Survey. The One-Percent Survey was one of DESI's survey validation programs conducted from April to May 2021, before the start of the main survey. It used the same target selection and similar observing strategy as the main survey and successfully observed the spectra and redshifts of 143,017 galaxies in the $r < 19.5$ magnitude-limited BGS Bright sample and 95,499 galaxies in the fainter surface brightness and color selected BGS Faint sample over $z < 0.6$. We derive pSMFs from posteriors of stellar mass, $M_*$, inferred from DESI photometry and spectroscopy using the Hahn et al. (2022a; arXiv:2202.01809) PRObabilistic Value-Added BGS (PROVABGS) Bayesian SED modeling framework. We use a hierarchical population inference framework that statistically and rigorously propagates the $M_*$ uncertainties. Furthermore, we include correction weights that account for the selection effects and incompleteness of the BGS observations. We present the redshift evolution of the pSMF in BGS as well as the pSMFs of star-forming and quiescent galaxies classified using average specific star formation rates from PROVABGS. Overall, the pSMFs show good agreement with previous stellar mass function measurements in the literature. Our pSMFs showcase the potential and statistical power of BGS, which in its main survey will observe >100$\times$ more galaxies. Moreover, we present the statistical framework for subsequent population statistics measurements using BGS, which will characterize the global galaxy population and scaling relations at low redshifts with unprecedented precision.Comment: 25 pages, 12 figures; data used to generate figures is available at https://doi.org/10.5281/zenodo.8018936; submitted to Ap

DESI Observations of the Andromeda Galaxy: Revealing the Immigration History of our Nearest Neighbor

We present DESI observations of the inner halo of M31, which reveal the kinematics of a recent merger - a galactic immigration event - in exquisite detail. Of the 11,416 sources studied in 3.75 hour of on-sky exposure time, 7,438 are M31 sources with well measured radial velocities. The observations reveal intricate coherent kinematic structure in the positions and velocities of individual stars: streams, wedges, and chevrons. While hints of coherent structures have been previously detected in M31, this is the first time they have been seen with such detail and clarity in a galaxy beyond the Milky Way. We find clear kinematic evidence for shell structures in the Giant Stellar Stream, the Northeast Shelf and Western Shelf regions. The kinematics are remarkably similar to the predictions of dynamical models constructed to explain the spatial morphology of the inner halo. The results are consistent with the interpretation that much of the substructure in the inner halo of M31 is produced by a single galactic immigration event 1 - 2 Gyr ago. Significant numbers of metal-rich stars ([Fe/H]$>-0.5$) are present in all of the detected substructures, suggesting that the immigrating galaxy had an extended star formation history. We also investigate the ability of the shells and Giant Stellar Stream to constrain the gravitational potential of M31, and estimate the mass within a projected radius of 125 kpc to be ${\rm log_{10}}\, M_{\rm NFW}(<125\,{\rm kpc})/M_\odot = 11.80_{-0.10}^{+0.12}$. The results herald a new era in our ability to study stars on a galactic scale and the immigration histories of galaxies.Comment: 45 pages, 22 figures, 8 tables; Astrophysical Journal in press; Data at https://zenodo.org/record/697749

Astro2020 APC White Paper: The MegaMapper: a z &gt; 2 spectroscopic instrument for the study of Inflation and Dark Energy

MegaMapper is a proposed ground-based experiment to measure Inflation parameters and Dark Energy from galaxy redshifts at

A Spectroscopic Road Map for Cosmic Frontier: DESI, DESI-II, Stage-5

In this white paper, we present an experimental road map for spectroscopic experiments beyond DESI. DESI will be a transformative cosmological survey in the 2020s, mapping 40 million galaxies and quasars and capturing a significant fraction of the available linear modes up to z=1.2. DESI-II will pilot observations of galaxies both at much higher densities and extending to higher redshifts. A Stage-5 experiment would build out those high-density and high-redshift observations, mapping hundreds of millions of stars and galaxies in three dimensions, to address the problems of inflation, dark energy, light relativistic species, and dark matter. These spectroscopic data will also complement the next generation of weak lensing, line intensity mapping and CMB experiments and allow them to reach their full potential.Comment: Contribution to Snowmass 202

Searching for dark matter annihilation in recently discovered Milky Way satellites with Fermi-LAT

We search for excess γ-ray emission coincident with the positions of confirmed and candidate Milky Way satellite galaxies using six years of data from the Fermi Large Area Telescope (LAT). Our sample of 45 stellar systems includes 28 kinematically confirmed dark-matter-dominated dwarf spheroidal galaxies (dSphs) and 17 recently discovered systems that have photometric characteristics consistent with the population of known dSphs. For each of these targets, the relative predicted γ-ray flux due to dark matter annihilation is taken from kinematic analysis if available, and estimated from a distance-based scaling relation otherwise, assuming that the stellar systems are DM-dominated dSphs. LAT data coincident with four of the newly discovered targets show a slight preference (each ~2σ local) for γ-ray emission in excess of the background. However, the ensemble of derived γ-ray flux upper limits for individual targets is consistent with the expectation from analyzing random blank-sky regions, and a combined analysis of the population of stellar systems yields no globally significant excess (global significance 1 TeV and mDM,t+t-> 70 GeV) and weakening by a factor of ~1.5 at lower masses relative to previously observed limits

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

BACKGROUND: Patient-reported measures can be used to examine whether drug differences other than clinical efficacy have an impact on outcomes that may be important to patients. Although exenatide and insulin glargine appear to have similar efficacy for treatment of type 2 diabetes, there are several differences between the two treatments that could influence outcomes from the patient's perspective. The purpose of the current study was to examine whether the two drugs were comparable as assessed by patient-reported outcomes using data from a clinical trial in which these injectable medications were added to pre-existing oral treatment regimens. METHODS: Patients were randomized to either twice daily exenatide or once daily insulin glargine during a 26-week international trial. At baseline and endpoint, five patient-reported outcome measures were administered: the Vitality Scale of the SF-36, The Diabetes Symptom Checklist – Revised (DSC-R), the EuroQol EQ-5D, the Treatment Flexibility Scale (TFS), and the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Change from baseline to endpoint was analyzed within each treatment group. Group differences were examined with General linear models (GLMs), controlling for country and baseline scores. RESULTS: A total of 549 patients with type 2 diabetes were enrolled in the trial, and current analyses were conducted with data from the 455 per protocol patients (228 exenatide and 227 insulin glargine). The sample was primarily Caucasian (79.6%), with slightly more men (55.2%) than women, and with a mean age of 58.5 years. Paired t-tests found that both treatment groups demonstrated statistically significant baseline to endpoint change on several of the health outcomes instruments including the DSC-R, DTSQ, and the SF-36 Vitality subscale. GLMs found no statistically significant differences between groups in change on the health outcomes instruments. CONCLUSION: This analysis found that both exenatide and insulin glargine were associated with significant improvements in patient-reported outcomes when added to oral medications among patients with type 2 diabetes. Despite an additional daily injection and a higher rate of gastrointestinal adverse events, treatment satisfaction in the exenatide group was comparable to that of the glargine group, possibly because of weight reduction observed in patients treated with exenatide